文献速递胰腺与胆道疾病消化内镜

内镜下置入可生物降解胆道支架治疗良性胆道狭窄和胆囊管漏的初步研究

A pilot study of endoscopically inserted biodegradable biliary stents in the treatment of benign biliary strictures and cystic duct leaks.
PubMed 文献 · Gastrointest Endosc · 2017-11-08

这项前瞻性研究纳入13例患者(5例女性,中位年龄67岁),因医源性胆囊管漏(7例)或良性胆道狭窄(6例)经内镜逆行胆管造影置入聚二氧环己酮可生物降解胆道支架。支架置入均成功,胆囊管漏均顺利治愈,良性胆道狭窄临床成功率为83%,中位随访21个月,早期不良事件包括胆管炎和胰腺炎各1例(8%)。

要点

  • 内镜下置入聚二氧环己酮可生物降解胆道支架在胆囊管漏和良性胆道狭窄中短期和长期安全性令人满意。
  • 良性胆道狭窄的临床成功率为83%,中位随访21个月(范围14-25个月)。
  • 支架留置期间出现轻度胆管炎似乎是可生物降解胆道支架的典型表现,早期胆管炎和胰腺炎各1例(8%)。

核心结论

  • 内镜下置入的聚二氧环己酮可生物降解胆道支架短期和长期安全性令人满意。
  • 胆囊管漏和良性远端胆总管狭窄的管理非常成功。
  • 支架留置期间出现轻度胆管炎似乎是可生物降解胆道支架的典型表现。
  • 可生物降解胆道支架的优点在于避免为取出支架而重复内镜操作。

研究设计与样本

  • 前瞻性研究,纳入提供知情同意的患者,2014年至2016年间经内镜逆行胆管造影置入编织自膨胀聚二氧环己酮可生物降解胆道支架。
  • 共13例患者,5例女性,中位年龄67岁(范围43-79岁),其中医源性胆囊管漏7例、良性胆道狭窄6例。
  • 随访期间重复进行肝功能检查和磁共振成像,主要结局为治疗成功和不良事件。

主要发现

  • 经内镜逆行胆管造影置入支架在所有病例中均成功。
  • 所有胆漏均经可生物降解胆道支架顺利治愈。
  • 良性胆道狭窄中可生物降解胆道支架治疗的临床成功率为83%,中位随访21个月(范围14-25个月)。
  • 早期内镜逆行胆管造影相关不良事件包括胆管炎1例(8%)和胰腺炎1例(8%),均发生在狭窄组。
  • 在最初90天内,23%的患者因轻度胆管炎再入院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Self-expanding biodegradable biliary stents (BDBSs) have recently become available for use in endoscopic retrograde cholangiography (ERC). The aim was to evaluate the effectiveness and safety of novel BDBSs in iatrogenic cystic duct leaks and benign biliary strictures (BBSs). METHODS: Patients providing informed consent were recruited for the prospective study. Braided self-expanding poly-dioxanone BDBSs were inserted using ERC during from 2014 to 2016. Repeated liver function tests and magnetic resonance imaging were performed during follow-up. The main outcomes were treatment success and adverse events. RESULTS: Thirteen patients, 5 women, median age 67 years (range, 43-79) underwent BDBS insertion for iatrogenic cystic duct leak (n = 7) or BBS (n = 6). Stent insertion using ERC was successful in all cases. All bile leaks were treated uneventfully with BDBSs. In BBSs, the clinical success rate of BDBS therapy was 83% in a median of 21 months of follow-up (range, 14-25). Early ERC-related adverse events included 1 cholangitis (8%) and 1 pancreatitis (8%), both in the stricture group. During the first 90 days, 23% of patients were readmitted for mild cholangitis. CONCLUSIONS: The short- and long-term safety of endoscopically inserted poly-dioxanone BDBSs was satisfactory. The management of cystic duct leaks and benign distal common bile duct strictures was highly successful. Episodes of mild cholangitis during stent indwelling seemed to be typical of BDBSs. The advantage of BDBSs is the avoidance of repeated endoscopy for stent removal. (Clinical trial registration number: NCT02353286.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Siiki A, Rinta-Kiikka I, Sand J, et al. A pilot study of endoscopically inserted biodegradable biliary stents in the treatment of benign biliary strictures and cystic duct leaks. Gastrointest Endosc. 2017. PMID: 29128386. doi:10.1016/j.gie.2017.10.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。